Drug Price Trends for NDC 00173-0882

Average Pharmacy Cost for 00173-0882

Drug Name	NDC	Price/Unit ($)	Unit	Date
BREO ELLIPTA 200-25 MCG INHALR	00173-0882-14	5.36254	EACH	2026-03-18
BREO ELLIPTA 200-25 MCG INHALR	00173-0882-10	6.50367	EACH	2026-03-18
BREO ELLIPTA 200-25 MCG INHALR	00173-0882-14	5.35857	EACH	2026-02-18

Best Wholesale Price for NDC 00173-0882

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
BREO ELLIPTA INHALER 200/25 MCG	GlaxoSmithKline	00173-0882-10	30	271.40	9.04667	2022-08-01 - 2027-07-31	Big4
BREO ELLIPTA INHALER 200/25 MCG	GlaxoSmithKline	00173-0882-10	30	316.66	10.55533	2022-08-01 - 2027-07-31	FSS
BREO ELLIPTA INHALER 200/25 MCG	GlaxoSmithKline	00173-0882-10	30	280.05	9.33500	2023-01-01 - 2027-07-31	Big4

Market Analysis and Price Projections for NDC 00173-0882

Last updated: February 15, 2026

Overview of the Drug

NDC 00173-0882 is the National Drug Code identifier for Darzalex (daratumumab), a monoclonal antibody developed by Janssen Pharmaceuticals. It is approved for the treatment of multiple myeloma, including newly diagnosed and relapsed/refractory cases.

Market Landscape

• Indications: Multiple myeloma (MM), both in newly diagnosed and relapsed/refractory settings.
• Market Penetration: Darzalex gained rapid acceptance following FDA approval in 2015, becoming a leading therapy in the MM segment.
• Competitors: Other monoclonal antibodies such as Elotuzumab, CAR T-cell therapies (ide-cel, Breyanzi), and conventional treatments like proteasome inhibitors and immunomodulatory drugs.
• Market Size: The global multiple myeloma drug market was valued at approximately $11.8 billion in 2021 and is projected to grow at a CAGR of 10-12% through 2028, driven by increased diagnosis rates and new combination regimens (source: Fortune Business Insights).

Current Market Share and Position

• Market Penetration: Darzalex holds a dominant position, with approximately 45-50% market share in the MM monoclonal antibody segment.
• Revenue: 2022 sales reached over $3.9 billion globally, indicating sustained demand.

Pricing Trends and Projections

• Current List Price: Approximately $4,300 per 10 mg vial, with treatment courses costing between $60,000 and $100,000 depending on dosing and duration.
• Pricing Variability: Prices vary by country, insurance coverage, and dosage adjustments.
• Reimbursements: Medicare, private insurers, and pharmacy benefit managers (PBMs) reimburse at limits that influence net pricing.

Price Dynamics

• The list price has increased steadily since FDA approval, reflecting inflation in biologic pricing and market demand.
• Pegged to the dosing schedule, the annual treatment cost generally falls within $60,000 to $120,000 for standard regimens.
• Competition and biosimilar development could pressure prices over the next 3-5 years. Biosimilars of daratumumab could enter the market by 2024-2025, potentially reducing prices by 20-50%.

Future Price Projections (Next 5 Years)

Year	Estimated List Price per Course	Assumptions	Notes
2023	$80,000 – $100,000	Stable demand, no significant biosimilar competition yet	Based on market growth, inflation, and current reimbursement trends
2024	$75,000 – $95,000	Biosimilar entries may begin to impact pricing	Price reductions expected due to biosimilar competition
2025	$70,000 – $90,000	Increased biosimilar availability, pricing pressures	Continued decline anticipated
2026	$65,000 – $85,000	Biosimilar market expansion	Potential for negotiated discounts and payer-driven price reductions
2027	$60,000 – $80,000	Market stabilization with biosimilar dominance	Price compression leveled, but biologic demand sustains revenues

Regulatory and Policy Influences

• Pricing pressures are likely to increase due to policies aiming to reduce biologic drug costs.
• Biosimilar approval regulations in key markets, including US and EU, will determine market penetration speed.
• Value-based pricing models are gaining traction in managed care, linking reimbursement to outcomes rather than list prices.

Key Risks and Opportunities

• Risks: Biosimilar competition, payer pushback, regulatory action on pricing.
• Opportunities: Adaptive dosing strategies, expanded indications, combination therapy approvals.

Summary

• NDC 00173-0882 (Darzalex) remains a high-value, growing therapy in multiple myeloma.
• Current list prices hover around $80,000 to $100,000 per treatment course.
• Prices are expected to decline gradually over 2024-2027 due to biosimilar competition and pricing pressures.
• Market share is durable but vulnerable to new therapeutic entrants.

---

Key Takeaways

• Darzalex's market remains strong, with sales surpassing $3.9 billion globally in 2022.
• Prices are likely to decline by approximately 10-20% over the next five years.
• Biosimilars could significantly impact pricing and market share starting in 2024.
• Reimbursement strategies and regulatory policies will shape future pricing dynamics.
• Continued innovation and expanded indications will sustain market relevance.

---

FAQs

1. What is the main competitive advantage of Darzalex?
   Its proven efficacy in multiple myeloma and established market presence.

2. When will biosimilars of daratumumab enter the market?
   Likely between 2024 and 2025, based on regulatory timelines and development progress.

3. How will biosimilar entry affect prices?
   Prices could drop by 20-50%, depending on market uptake and payer strategies.

4. Are there clinical or regulatory factors that could boost Darzalex’s sales?
   New approved combination regimens and expanded indications.

5. What are the main risks to the current price projections?
   Accelerated biosimilar competition, new therapeutic breakthroughs, and payer restrictions.

---

Sources

1. Fortune Business Insights, "Multiple Myeloma Drugs Market Size, Share & Industry Analysis," 2022.
2. Janssen Pharmaceuticals, "Darzalex (daratumumab): Clinical Data," 2022.
3. IQVIA Institute, "The Global Use of Medicine in 2021," 2022.
4. FDA, "Daratumumab (Darzalex) Prescribing Information," 2015.
5. Centers for Medicare & Medicaid Services, "Medicare Part B Drug Payment Data," 2022.